Bleakley Financial Group LLC Lowers Stake in Cencora, Inc. (NYSE:COR)

Bleakley Financial Group LLC lowered its position in Cencora, Inc. (NYSE:COR - Free Report) by 12.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,879 shares of the company's stock after selling 1,349 shares during the period. Bleakley Financial Group LLC's holdings in Cencora were worth $2,220,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Concord Wealth Partners acquired a new position in Cencora during the 3rd quarter valued at approximately $30,000. Householder Group Estate & Retirement Specialist LLC increased its stake in shares of Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in Cencora in the 3rd quarter valued at $41,000. Modus Advisors LLC purchased a new stake in Cencora in the 4th quarter valued at $54,000. Finally, Carolina Wealth Advisors LLC increased its stake in Cencora by 366.7% during the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company's stock worth $60,000 after acquiring an additional 209 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares of the company's stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,187 shares of company stock valued at $17,790,912. 10.80% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on COR shares. JPMorgan Chase & Co. increased their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. UBS Group increased their price objective on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Wells Fargo & Company boosted their price objective on shares of Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a research report on Wednesday, January 29th. Robert W. Baird lifted their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Finally, Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and a consensus price target of $277.90.

Cencora Stock Up 0.2 %

Shares of COR stock traded up $0.48 on Tuesday, hitting $246.86. 1,076,644 shares of the stock were exchanged, compared to its average volume of 1,476,687. The firm has a market capitalization of $47.71 billion, a P/E ratio of 35.11, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The business has a 50-day moving average of $238.86 and a 200 day moving average of $237.03. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities analysts anticipate that Cencora, Inc. will post 15.36 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date is Friday, February 14th. Cencora's dividend payout ratio (DPR) is presently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.